SCHEDULE 13D/A: 23andMe Co-Founder Anne Wojcicki Proposes Take-Private Deal Valued at Up to $2.94 Per Share Amidst Bankruptcy Risk

23andMe Holding Co-founder Anne Wojcicki has submitted a revised non-binding proposal to acquire all outstanding shares not owned by her and affiliates for up to $2.94 per share, including upfront cash and contingent value rights, aiming to take the company private to avoid bankruptcy.

Summary

• Anne Wojcicki, co-founder of 23andMe, has submitted a revised non-binding proposal to acquire all outstanding shares of 23andMe Holding Co. not owned by her and her affiliates.
• The proposal offers total consideration of up to $2.94 per share, comprising $0.41 per share in upfront cash and three contingent value rights (CVRs) totaling an additional $2.53 per share.
• The CVRs are tied to future revenue milestones: $0.67 per share if fiscal year 2026 revenue exceeds $224 million, $0.84 per share if fiscal year 2027 revenue exceeds $295 million, and $1.01 per share if fiscal year 2028 revenue exceeds $367 million.
• Wojcicki is willing to provide $30 million in unsecured financing to the company at a 7% interest rate to fund operations through the closing of the potential transaction.
• The proposal is made in the context of the company risking bankruptcy, with the aim of taking 23andMe private to focus on long-term value creation and ensure customer data control.
• The transaction is subject to negotiation of definitive documentation, customary governmental consents, absence of material adverse change, and requires approval from the Special Committee and a majority of shares not owned by Wojcicki or rollover stockholders.
• The closing of the transaction will not be subject to any financing contingency.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the explicit mention of bankruptcy risk and the low upfront cash component of the offer. While the proposal offers a potential lifeline and a path to privatization, the underlying financial distress and the contingent nature of most of the proposed value weigh heavily on the sentiment. It's a rescue offer, not a growth-driven acquisition.

Positives

• The proposal offers a potential path to avoid bankruptcy for 23andMe, which could negatively impact the brand, employees, customers, and stockholders.
• The upfront cash component of $0.41 per share provides immediate liquidity to public stockholders.
• The contingent value rights (CVRs) offer potential additional value of up to $2.53 per share, incentivizing future revenue growth.
• Anne Wojcicki is willing to provide $30 million in unsecured financing to support company operations through the transaction closing, demonstrating commitment and addressing immediate liquidity needs.
• The proposal is not subject to a financing contingency, reducing uncertainty regarding deal completion.
• The requirement for approval by a majority of shares not owned by Wojcicki or affiliates ensures minority shareholder protection.

Negatives

• The total consideration of up to $2.94 per share is significantly dependent on the achievement of future revenue milestones, with only $0.41 per share guaranteed upfront.
• The CVRs are non-tradable, limiting liquidity for the contingent portion of the consideration.
• The company is explicitly stated to be "risking bankruptcy," indicating severe financial distress.
• The proposal is non-binding and subject to negotiation, with no assurance that a definitive agreement will be reached or that the transaction will occur.
• The reporting persons reserve the right to modify or withdraw the proposal at any time.

Risks

• Bankruptcy Risk: The company is explicitly stated to be "risking bankruptcy," which would negatively impact the brand, harm relationships with employees and customers, and generate nothing for stockholders.
• Contingent Value Rights (CVRs) Uncertainty: A significant portion of the proposed value ($2.53 per share) is contingent on achieving specific revenue milestones in fiscal years 2026, 2027, and 2028, which may not be met.
• Non-Tradable CVRs: The CVRs are structured as a contract and are non-tradable, meaning stockholders cannot sell them for immediate value, and their value is only realized upon milestone achievement.
• Transaction Uncertainty: The proposal is non-binding and subject to negotiation and execution of definitive documentation, with no guarantee that a transaction will be consummated.
• Material Adverse Change Clause: The closing is subject to the absence of any material adverse change in the company's business, assets, condition, results of operations, cash flows, or properties, which could provide an out for the acquirer.
• Withdrawal Risk: The reporting persons reserve the right to modify or withdraw the proposal at any time without prior notice.
• Liquidity Risk: Taking the company private would remove its public listing, eliminating liquidity for remaining public shareholders (if any, though the proposal is for all outstanding shares).

Future Outlook

The proposal aims to take 23andMe private to allow the company to focus on long-term value creation, away from public market pressures, while ensuring customer data remains central. However, there is no assurance that the proposal will result in a definitive agreement or transaction, and the reporting persons reserve the right to modify or withdraw it.

Management Comments

• "Ever since I co-founded 23andMe in 2006, I have always tried to do what is best for the company, employees, customers and stockholders."
• "Despite our work to restructure the business, the company risks bankruptcy a process which would negatively impact our brand, harm our relationships with employees and customers, and generate nothing for our stockholders."
• "I have been working tirelessly to avoid this from happening."
• "We ran an exhaustive process to identify new financing, contacting over 100 potential providers of public and private equity as well as debt financing."
• "I also allowed the Special Committee to solicit additional M&A interest."
• "Over the past eighteen years, 23andMe has been built putting individuals at the center and in control of their genetic information and empowering them to access, understand and benefit from the human genome."
• "I am committed to charting a path that allows the company to focus on long-term value creation as a private company while also ensuring our over 15 million customers remain at the center of their data with choice and transparency."
• "I continue to believe that an acquisition by me, which would provide compelling value and immediate and future liquidity to the company's public stockholders, is what is best for the company."

Industry Context

This proposal highlights the challenges faced by some direct-to-consumer genomics companies, particularly in achieving sustained profitability and navigating public market expectations. The move to take the company private suggests a belief that long-term value creation, especially in a data-intensive and research-heavy field like genomics, may be better pursued outside the scrutiny and short-term pressures of public markets. The explicit mention of bankruptcy risk underscores the financial difficulties that can arise even for well-known companies in innovative but capital-intensive sectors. The focus on customer data control and transparency also reflects ongoing industry and regulatory discussions around data privacy in the genomics space.

Corporate Governance

Related Party Transactions

• The proposal itself is a related-party transaction, as it involves the co-founder and significant shareholder, Anne Wojcicki, acquiring the remaining shares of the company.
• Anne Wojcicki is offering to provide $30 million in unsecured financing to the company at a 7% interest rate.
• Anne Wojcicki's rollover equity of $2 million and new capital of $10 million are part of the transaction's funding.

Stakeholder Impact

• Shareholders: Public stockholders would receive upfront cash and potential CVRs, offering a potential exit from a company "risking bankruptcy." However, the CVRs are non-tradable and contingent, and the overall value might be lower than historical highs. Minority shareholders are protected by the required majority-of-the-minority vote.
• Employees: The proposal aims to avoid bankruptcy, which would "negatively impact our brand, harm our relationships with employees." Taking the company private could provide stability and a clearer long-term focus, potentially benefiting employees by securing their jobs and future.
• Customers: The proposal emphasizes keeping "over 15 million customers... at the center of their data with choice and transparency," suggesting a commitment to customer trust and data privacy even under private ownership. Avoiding bankruptcy would also ensure continued service.
• Creditors: The $30 million unsecured financing offered by Anne Wojcicki could provide immediate liquidity, potentially improving the company's ability to meet its obligations, though the interest rate is 7%.
• Suppliers: Avoiding bankruptcy would ensure continued business operations, which would benefit suppliers by maintaining their contracts and revenue streams from 23andMe.

Next Steps

• Negotiation and execution of mutually agreeable definitive documentation for the Potential Transaction.
• Receipt of all material governmental consents and approvals.
• Approval of the Special Committee of the Board of Directors.
• Approval of a majority of the shares of common stock of the Company not owned by Anne Wojcicki, any other stockholders invited to roll over their shares, or their respective affiliates.
• Anne Wojcicki and her advisors (Skadden, Arps, Slate, Meagher & Flom LLP and TD Cowen) will work with the Special Committee to quickly execute definitive transaction agreements.
• Reporting Persons intend to engage in discussions with the Special Committee regarding the terms of the March 6 Proposal.
• Reporting Persons may change the terms, accelerate/terminate discussions, withdraw the proposal, or take other actions to facilitate the proposal.
• Reporting Persons will continue to take steps to further the proposal or support their investment, including discussions with advisors and relevant parties, and entering into agreements.

Key Dates

Recommendation

Keywords

23andMe Holding Co., Anne Wojcicki, Take-private, Privatization, Contingent Value Rights, CVR, Bankruptcy risk, SEC filing, Schedule 13D/A, Genetic information, Biotechnology, Genomics, Acquisition proposal, Shareholder value, Corporate governance